Related Experiment Videos
[Prolactin secretion in Cushing's syndrome].
Problemy Endokrinologii
|July 1, 1981
Summary
In active Icenko-Cushing's disease, prolactin levels rise and pituitary response to stress decreases. Chloditan treatment for remission did not normalize prolactin or pituitary function.
Area of Science:
- Endocrinology
- Neuroendocrinology
Background:
- Icenko-Cushing's disease is characterized by excessive cortisol production.
- Prolactin secretion is regulated by complex neuroendocrine pathways.
- Adrenocortical inhibitors like chloditan are used to manage hypercortisolism.
Purpose of the Study:
- To investigate prolactin secretion patterns in patients with Icenko-Cushing's disease.
- To assess the impact of chloditan treatment on prolactin levels and pituitary response.
- To evaluate pituitary reactivity to stress during active disease and remission.
Main Methods:
- Radioimmunoassay was used to measure blood prolactin concentrations.
- Tests involved insulin-induced hypoglycemia and thyroliberin stimulation.
- Measurements were taken in 30 patients with Icenko-Cushing's disease (active and remission stages).
Main Results:
- Elevated basal prolactin levels were observed in the active stage of Icenko-Cushing's disease.
- Reduced pituitary response to insulin hypoglycemia and thyroliberin stimulation occurred in the active stage.
- Chloditan treatment leading to clinical remission did not restore normal prolactin levels or pituitary responsiveness.
Conclusions:
- Active Icenko-Cushing's disease is associated with altered prolactin secretion and blunted pituitary responses.
- Chloditan therapy, while effective for hypercortisolism, does not fully normalize prolactin dynamics or pituitary function.
- Further research is needed to understand the long-term neuroendocrine effects of Icenko-Cushing's disease and its treatment.